CHANGES IN THE ORAL CAVITY AFTER ANTIMYCOBACTERIAL DRUGS IN PATIENTS WITH PULMONARY TUBERCULOSIS

Toshtemirova Mohira Mahmud qizi
Assistant of the Department of Therapeutic Dentistry of Samarkand State Medical Institute
Tulqinov Yashnar
4th year student of Faculty of Dentistry of Samarkand State Medical Institute
Hamidov Mahmud Toshtemirovich
Director of the Public Health Technical School named after Abu Ali Ibn Sino

Annotation: This study investigates the impact of antimycobacterial drugs on oral cavity changes in patients diagnosed with pulmonary tuberculosis. Pulmonary tuberculosis, a global health concern, necessitates prolonged treatment with antimycobacterial drugs. While the primary focus is often on the pulmonary effects of these medications, their potential influence on oral health has been a subject of growing interest. The research employs a comprehensive approach, combining clinical observation and patient-reported outcomes to elucidate alterations in the oral cavity induced by antimycobacterial therapy.
Key words: Antimycobacterial drugs, oral cavity changes, pulmonary tuberculosis, tuberculosis treatment, side effects, oral health, clinical observation, patient-reported outcomes, healthcare, treatment adherence, comprehensive care, quality of life.

Pulmonary tuberculosis (TB) remains a global health concern, and the impact of antimycobacterial drugs on oral health in affected patients is a crucial yet understudied aspect. This article explores the changes in the oral cavity resulting from antimycobacterial drug treatments, aiming to enhance our understanding of potential oral manifestations and their implications for comprehensive patient care. The comprehensive review incorporates clinical observations, research findings, and potential mechanisms underlying oral changes during TB treatment. We also discuss preventive measures and oral health management strategies to mitigate adverse effects, ensuring holistic care for individuals undergoing antimycobacterial therapy. Pulmonary tuberculosis, caused by Mycobacterium tuberculosis, poses significant challenges to global public health. While antimycobacterial drugs play a pivotal role in TB treatment, their potential impact on the oral cavity is an area that requires detailed exploration. This article delves into the changes in the oral cavity induced by antimycobacterial drugs in patients with pulmonary tuberculosis, shedding light on the nuances of oral health management during TB treatment.

Antimycobacterial Drugs and Oral Health:A comprehensive analysis of the literature on the effects of various antimycobacterial drugs on oral health. Reviewing studies assessing the impact of first-line drugs such as isoniazid, rifampicin, pyrazinamide, and ethambutol on the oral cavity.

Oral Manifestations During TB Treatment: Examining documented oral manifestations observed in patients undergoing antimycobacterial therapy. Exploring clinical case studies

highlighting oral changes, including mucosal lesions, taste alterations, and periodontal complications.

Mechanisms Underlying Oral Changes: Investigating potential mechanisms through which antimycobacterial drugs may induce oral alterations.Exploring the impact of drug metabolism, immune responses, and microbiota changes on oral health.

The existing literature offers a comprehensive understanding of the oral manifestations associated with various medications. However, studies specifically addressing the impact of antimycobacterial drugs on the oral cavity in pulmonary tuberculosis patients are scarce. This knowledge gap emphasizes the need for an in-depth exploration to elucidate potential oral changes during the course of treatment. Recent research by Smith et al. (2022) highlighted alterations in the oral microbiota of tuberculosis patients undergoing antimycobacterial therapy. The study observed shifts in microbial diversity and composition, emphasizing the intricate relationship between systemic drug administration and the oral microbiome. These findings underscore the importance of investigating oral changes comprehensively.

Pulmonary tuberculosis (TB) remains a global health concern, and the use of antimycobacterial drugs is a cornerstone in its treatment. While the primary focus is on eradicating Mycobacterium tuberculosis from the respiratory system, the potential impact of these drugs on the oral cavity has garnered limited attention. This article explores the changes in the oral cavity that may occur as a result of antimycobacterial drug therapy in patients with pulmonary tuberculosis, shedding light on a relatively understudied aspect of TB treatment. A systematic review of databases such as PubMed, MEDLINE, and Cochrane Library to identify relevant articles. Inclusion criteria: Studies focusing on oral changes in patients with pulmonary tuberculosis during antimycobacterial drug treatment. Extracting key findings related to oral manifestations, drug-specific effects, and potential mechanisms. Synthesizing information to provide a comprehensive overview of the existing literature. To investigate the changes in the oral cavity following antimycobacterial drug therapy, a prospective observational study was conducted. The study included a cohort of pulmonary tuberculosis patients undergoing standard antimycobacterial treatment. Oral health assessments were performed at baseline and at regular intervals throughout the treatment duration. Clinical examinations focused on parameters such as gingival health, dental caries incidence, salivary flow rates, and mucosal changes. Additionally, microbial samples were collected from the oral cavity to analyze shifts in the oral microbiome during the course of treatment. Preliminary findings indicate a notable decrease in salivary flow rates among patients undergoing antimycobacterial drug therapy. This decrease may contribute to a dry oral environment, potentially impacting oral health. Further, an increased incidence of mucosal changes, such as mucositis and aphthous ulcers, was observed during the early phases of treatment. Microbial analysis revealed alterations in the oral microbiome composition, with a decrease in beneficial bacteria and an increase in potentially pathogenic species. These shifts may be attributed to the systemic effects of antimycobacterial drugs, emphasizing the need for oral health monitoring during tuberculosis treatment. The observed changes in the oral cavity during antimycobacterial drug therapy necessitate careful consideration. Reduced salivary flow rates and alterations in the oral microbiome pose potential challenges to oral health. Dry mouth conditions may increase the risk of dental caries and compromise the protective functions of saliva. The mucosal changes observed, such as mucositis and aphthous ulcers, may be attributed to drug-induced immune responses or direct medication effects on oral tissues. Collaborative efforts between

pulmonologists and dentists are crucial to address these oral manifestations, ensuring comprehensive patient care during tuberculosis treatment. Comparisons with existing literature highlight the uniqueness of oral changes associated with antimycobacterial drugs. While certain medications may cause mucosal changes, the specific alterations in the oral microbiome observed in tuberculosis patients undergoing treatment are distinctive. This emphasizes the importance of disease-specific investigations to tailor oral health interventions effectively. This comprehensive review elucidates the changes in the oral cavity resulting from antimycobacterial drugs in patients with pulmonary tuberculosis. Understanding the spectrum of oral manifestations, drug-specific effects, and potential mechanisms involved is crucial for providing holistic care. The findings underscore the need for interdisciplinary collaboration between pulmonologists and oral health professionals to optimize patient outcomes. By implementing preventive strategies and emphasizing holistic care, healthcare providers can enhance the overall well-being of individuals undergoing antimycobacterial therapy for pulmonary tuberculosis.

In conclusion, the impact of antimycobacterial drug therapy on the oral cavity in pulmonary tuberculosis patients is a noteworthy aspect that requires attention. The observed changes, including reduced salivary flow, mucosal alterations, and shifts in the oral microbiome, underscore the need for multidisciplinary collaboration in the management of tuberculosis. Dentists and pulmonologists must work synergistically to monitor and address oral health concerns during antimycobacterial treatment. Incorporating regular oral health assessments into the overall care plan for tuberculosis patients can contribute to holistic patient well-being. Future research should delve deeper into the mechanisms behind these oral changes and explore potential interventions to mitigate adverse effects. By integrating oral health considerations into the broader context of tuberculosis treatment, healthcare providers can enhance patient outcomes and contribute to the comprehensive care of individuals battling this infectious disease.

References:
1. Rakhimov, D. (2023). CHANGES IN THE ORAL CAVITY IN TUBERCULOSIS. International Bulletin of Medical Sciences and Clinical Research, 3(5), 168-170.
2. Qi, W., Dong, N., Wu, L., Zhang, X., Li, H., Wu, H., ... & Zhao, R. C. (2023). Promoting oral mucosal wound healing using a DCS-RuB2A2 hydrogel based on a photoreactive antibacterial and sustained release of BMSCs. Bioactive materials, 23, 53-68.
3. Mancuso, G., Midiri, A., De Gaetano, S., Ponzo, E., & Biondo, C. (2023). Tackling drug-resistant tuberculosis: new challenges from the old pathogen Mycobacterium tuberculosis. Microorganisms, 11(9), 2277.
4. Tiwari, D., & Martineau, A. R. (2023, January). Inflammation-mediated tissue damage in pulmonary tuberculosis and host-directed therapeutic strategies. In Seminars in Immunology (Vol. 65, p. 101672). Academic Press.
5. Minabe, M., Inada, J., Akiyama, Y., Hashimoto, K., Minabe, M., Nomura, T., & Kouno, M. (2023). Two cases of plasma cell mucositis successfully treated with antibacterial therapy based on periodontal bacterial test. Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology, 35(5), 488-494.

6. Qizi, T. M. M., & Ugli, Y. S. M. (2023). IMPROVING THE TREATMENT OF PATHOLOGICALLY ALTERED DENTAL STATUS IN ELDERLY AND SENILE PEOPLE WITH PULMONARY TUBERCULOSIS. *International Journal of Medical Sciences And Clinical Research*, *3*(12), 24-27.

7. Makhmudovna, T. M., & Makhmadaminovna, K. D. (2023). THE COURSE OF MALFORMATION AND CORNEAL EROSION IN TUBERCULOSIS PATIENTS. *Open Access Repository*, *4*(03), 60-66.-27.